M. Hunter is characterized by an accumulation of mucopolysaccharides in cells, blood, and connective tissue as a consequence of a deficiency of the enzyme iduronate-2-sulfatase. Unlike enzyme replacement therapy with idursulfase in children, there is limited long-term experience in adult patients with Morbus Hunter.
The case presented here describes the development of a man born in 1971 who was admitted to Hemer Lung Clinic in 2005 with severe obstructive sleep apnea, pulmonary functional impairment, and ventilatory failure (FEV 1: 0.8 L, VC: 1.0 L; pO2: 52 mmHg; pCO2: 81 mmHg, 6 MWT: 100 m). Initially, the patient received symptomatic treatment with noninvasive ventilation, which achieved a considerable improvement in pulmonary function and a normalization of blood gasses. Since February 2008, the patient received additional enzyme replacement therapy with idursulfase, which resulted in a further significant functional improvement (FEV1: 1.6; VC: 2.3 L; VO2max: 1,350 mL or 28.1 mL/kg body weight), in a normalization of prior elevated pulmonary artery pressures and also in impressive changes in the physiognomy and joint mobility. In November 2010, the polysomnography and nocturnal blood gas analysis without NIV showed only a mild obstructive sleep-related breathing disorder with no sign of hypoventilation. Therapy was changed to nocturnal CPAP therapy with a constant pressure of 6 cm H2O. Additional administration of oxygen was not required. With this therapy, the patient has been asymptomatic up to September 2011.
Adult Hunter patients also benefit from enzyme replacement therapy and, in restrictive ventilatory defects with hypoventilation, from symptomatic therapy with noninvasive ventilation.
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Six-minute walk test
Blood gas analysis
Continuous positive airway pressure
Diffusing capacity of the lung for carbon monoxide
Forced expiratory volume in 1 s
Forced vital capacity
Inter ventricular septum
Negative airway pressure
Pulmonary artery systolic pressure
Partial pressure of carbon dioxide
Maximal inspiration pressure
Partial pressure of oxygen
Total lung capacity
Maximum oxygen uptake
This is a preview of subscription content, log in to check access.
Baehner F, Schmiedeskamp C, Krummenauer F et al (2005) Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 28:1011–1017PubMedCrossRefGoogle Scholar
Beck M (2011) Mucopolysaccharidosis Type II (Hunter Syndrome): clinical picture and treatment. Curr Pharm Biotechnol 12:861–866PubMedCrossRefGoogle Scholar
Burrow TA, Leslie ND (2008) Review of the use of idursulfase in the treatment of mucopolysaccharidosis II. Biologics 2:311–320PubMedGoogle Scholar
Davitt SM, Hatrick A, Sabharwal T, Pearce A, Gleeson M, Adam A (2002) Tracheobronchial stent insertions in the management of major airway obstruction in a patient with Hunter syndrome (type II mucopolysaccharidosis). Eur Radiol 12:458–462PubMedCrossRefGoogle Scholar
Ginzburg AS, Onal E, Aronson RM, Schild JA, Mafee MF, Lopata M (1990) Successful use of nasal-CPAP for obstructive sleep apnea in Hunter syndrome with diffuse airway involvement. Chest 97:1496–1498PubMedCrossRefGoogle Scholar
Jones SA, Almássy Z, Beck M et al (2009) Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 32:534–543PubMedCrossRefGoogle Scholar
Kamin W (2008) Diagnosis and management of respiratory involvement in Hunter syndrome. Acta Paediatr 97:57–60CrossRefGoogle Scholar
Kurihara M, Kumagai K, Goto K, Imai M, Yagishita S (1992) Severe type Hunter´s syndrome. Polysomnographic and neuropathological study. Neuropediatrics 23:248–256PubMedCrossRefGoogle Scholar
Le Guern E, Couillin P, Oberlé I, Ravise N, Boue J (1990) More precise localization of the gene for Hunter syndrome. Genomics 7:358–362PubMedCrossRefGoogle Scholar
Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R (2001) Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol 58:127–138PubMedCrossRefGoogle Scholar
Martin R, Beck M, Eng C et al (2008) Recognition and diagnosis of mucopolysaccaridosis II (Hunter syndrome). Pediatrics 121:e377–e386PubMedCrossRefGoogle Scholar
Morehead JM, Parsons DS (1993) Tracheobronchomalacia in Hunter´s syndrome. Int J Pediatr Otorhinolaryngol 26:255–261PubMedCrossRefGoogle Scholar
Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473PubMedCrossRefGoogle Scholar
Muenzer J, Beck M, Eng CM et al (2009) Multidisciplinary management of Hunter syndrome. Pediatrics 124:e1228–e1239PubMedCrossRefGoogle Scholar
Neufeld EF, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS et al (eds) The metabolic and molecular bases of inherited disease, 8th edn. Mc Graw-Hill, New York, pp 3421–3452Google Scholar
Okuyama T, Tanaka A, Suzuki Y et al (2010) Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II). Mol Genet Metab 99:18–25PubMedCrossRefGoogle Scholar
Orliaguet O, Pépin JL, Veale D, Kelkel E, Pinel N, Lévy P (1999) Hunter´s syndrome and associated sleep apnoea cured by CPAP and surgery. Eur Respir J 13:1195–1197PubMedCrossRefGoogle Scholar
Pérez-Calvo J, Bergua Sanclemente I, López Moreno MJ et al (2011) Early response to idursulfase in a 31-year old male patient with Hunter syndrome. Rev Clin Esp 211:e42–e45PubMedCrossRefGoogle Scholar
Sasaki CT, Ruiz R, Gaito R Jr, Kirchner JA, Seshi B (1987) Hunter’s syndrome: a study in airway obstruction. Laryngoscope 97:280–285PubMedCrossRefGoogle Scholar
Shapiro J, Strome M, Crocker AC (1985) Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann Otol Rhinol Laryngol 94:458–461PubMedGoogle Scholar
Wraith JE, Scarpa M, Beck M et al (2008) Mucopolysaccaridosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267–277PubMedCrossRefGoogle Scholar
Yoskovith A, Tewfik TL, Brouillette RT, Schloss MD, Der Kaloustian VM (1998) Acute airway obstruction in Hunter syndrome. Int J Pediatr Otorhinolaryngol 44:273–278CrossRefGoogle Scholar